✓ Credit card payment restored — secure checkout via Privacy Shield

Anaridex

✅ Reduces breast cancer risk
✅ Inhibits estrogen production
✅ Treats hormone receptor-positive
✅ Slows cancer progression
✅ Manages postmenopausal symptoms

Anaridex contains Anastrozole

Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience  · Last reviewed: May 2026

Buy more, save more Price per tablet
30 Tablet/s
US$0.70/tablet
US$21.00
60 Tablet/s
US$0.67/tablet · save 5%
US$40.00
90 Tablet/s
US$0.62/tablet · save 11%
US$56.00
180 Tablet/s BEST VALUE
US$0.61/tablet · save 13%
US$110.00
Encrypted checkout
Crypto pays 10% less
Discreet worldwide delivery
1,400+ customers · 50+ countries

⚡ Quick Answer — What is Anaridex?

Anaridex is an oral tablet from Cipla containing anastrozole 1 mg — a selective third-generation aromatase inhibitor. First-line adjuvant and metastatic therapy for hormone-receptor-positive breast cancer in postmenopausal women. Standard dose: 1 mg once daily, typically for 5–10 years in adjuvant setting. Anastrozole works by blocking conversion of androgens to oestrogen in peripheral tissue (~95% suppression). Postmenopausal women only — ineffective in premenopausal women (use tamoxifen instead). Main side effects: hot flushes, joint and muscle pain (arthralgia in 30%), bone-density loss with fracture risk, vaginal dryness, mood change. Mandatory: baseline DEXA scan + repeat every 2 years; calcium + vitamin D supplementation; consider bisphosphonate or denosumab if osteopenia.

What you get with MedsBase: WHO-GMP certified manufacturer · Discreet packaging · Worldwide shipping · 1,400+ verified customer reviews

📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.

⚠ Specialist supervision required. Cancer medications must be prescribed by a treating oncologist with a confirmed diagnosis, baseline staging, and a defined treatment plan. Never start, stop, change dose, or use cancer medication outside of an oncology-led care plan. Most cancer drugs require regular blood-test monitoring (FBC, LFT, renal function), are absolutely contraindicated in pregnancy, and have significant drug interactions.
🔒 Encrypted Checkout · 💳 Verified Processor · 🚚 Worldwide Shipping · ⭐ 4.9/5 from 1,400+ customers

What Is Anaridex?

Anaridex is an oral tablet from Cipla containing anastrozole 1 mg. Anastrozole is a third-generation, non-steroidal, selective aromatase inhibitor used for adjuvant and metastatic treatment of hormone-receptor-positive (HR+) breast cancer in postmenopausal women. Originally developed by AstraZeneca (brand name Arimidex), anastrozole is now a generic standard of care. It is one of the three most-prescribed aromatase inhibitors worldwide alongside exemestane and letrozole.

How Does Anaridex Work?

In postmenopausal women, ovarian oestrogen production has stopped — circulating oestrogen comes almost entirely from peripheral conversion of adrenal and gonadal androgens (androstenedione, testosterone) by the enzyme aromatase in fat, muscle, liver and breast tissue. Anastrozole reversibly inhibits aromatase, suppressing peripheral oestrogen synthesis by approximately 95% within 24–48 hours.

  • Selective non-steroidal aromatase inhibitor — competes with androgen substrate at the aromatase active site without binding the oestrogen receptor itself.
  • Postmenopausal-only mechanism — in premenopausal women, the hypothalamic-pituitary-ovarian axis compensates by raising LH/FSH and increasing ovarian aromatase, defeating the suppression. Anastrozole is ineffective in premenopausal women.
  • Reversible binding — effect ends within 7–10 days of discontinuation as new aromatase enzyme is synthesised.

Uses and Indications

  • Adjuvant therapy for early HR+ breast cancer in postmenopausal women, typically for 5 years (extended to 10 years in higher-risk disease)
  • First-line metastatic HR+ breast cancer in postmenopausal women, often combined with a CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib)
  • Sequential therapy after 2–3 years of tamoxifen, switching to an AI for completion of 5–10 years total endocrine therapy
  • Off-label: ovulation induction in fertility (specialist use), gynaecomastia in men on testosterone (specialist), male breast cancer (rare)

Anaridex is not indicated for: premenopausal women (use tamoxifen, or AI + ovarian suppression under specialist guidance), HR-negative breast cancer (no benefit), or non-cancer cosmetic indications.

Anaridex Dosage and How to Take

Standard dose: 1 mg once daily. Typical course length:

  • Adjuvant breast cancer: 5 years (10 years in high-risk node-positive disease, per ATLAS / aTTom data extrapolated to AIs)
  • Metastatic breast cancer: until disease progression or unacceptable toxicity

How to Take Anaridex Properly

  1. Take one tablet once daily at approximately the same time each day. Morning or evening — the half-life (~50 hours) means timing has minimal effect on steady-state levels.
  2. With or without food.
  3. Swallow whole with water.
  4. Mandatory monitoring: baseline DEXA bone-density scan, repeat every 2 years. Annual cholesterol panel. Lipid management as needed.
  5. Bone protection: calcium 1,000–1,200 mg/day + vitamin D 800–2,000 IU/day. If osteopenia at baseline or develops, add a bisphosphonate (zoledronic acid IV every 6 months) or denosumab (60 mg SC every 6 months) as standard of care.
  6. Joint pain management: regular weight-bearing exercise reduces arthralgia. Paracetamol or NSAIDs for symptomatic relief. Switching to letrozole or exemestane sometimes helps if anastrozole arthralgia is intolerable.
  7. Do not stop without oncologist instruction. Discontinuation before completion of the planned course significantly increases recurrence risk.
  8. Missed dose: if remembered same day, take it. If next day, skip and resume normally — do not double-dose.

Side Effects of Anaridex

Common (oestrogen-deprivation symptoms):

  • Hot flushes and night sweats (35–40%)
  • Arthralgia (joint pain, stiffness, especially morning) — 30% of patients; main cause of discontinuation
  • Myalgia (muscle aches)
  • Vaginal dryness, dyspareunia
  • Mood changes, low energy
  • Hair thinning
  • Mild nausea

Important long-term:

  • Accelerated bone-density loss — fracture risk increased ~30% versus tamoxifen. Mandatory DEXA monitoring and bone-protection.
  • Hyperlipidaemia (small increase in total cholesterol and LDL)
  • Carpal tunnel syndrome

Less common but seek review:

  • Ischaemic cardiac events (small absolute increase, mainly in patients with prior cardiac disease)
  • Hepatotoxicity (mild LFT rises common; severe rare)
  • Endometrial cancer signal — lower than with tamoxifen, slightly higher than placebo
  • Severe hypersensitivity (rare)

Warnings and Precautions

  • Pregnancy: ABSOLUTE CONTRAINDICATION. Anastrozole is teratogenic in animal models. Postmenopausal patients are usually past childbearing potential, but perimenopausal patients require contraception.
  • Premenopausal women: ineffective unless combined with ovarian suppression (GnRH agonist) under specialist oncologist supervision. Default to tamoxifen in premenopausal HR+ breast cancer.
  • Bone health: baseline DEXA before starting; repeat every 2 years. Calcium + vitamin D supplementation. Consider bisphosphonate or denosumab if osteopenia.
  • Cardiovascular: small increase in ischaemic cardiac events versus tamoxifen. Address modifiable risk factors. Monitor lipids annually.
  • Severe hepatic impairment: caution — limited data.
  • Concurrent oestrogen therapy (oestrogen-containing HRT or vaginal oestrogen): avoid — defeats the purpose of treatment.

Drug Interactions

Combine withEffectWhat to do
Oestrogen-containing HRT or vaginal oestrogenDefeats anastrozole's mechanism — treatment failsAvoid all systemic and high-dose vaginal oestrogen. Use non-hormonal vaginal moisturisers. Specialist for low-dose vaginal oestriol if symptoms intolerable.
TamoxifenTamoxifen reduces anastrozole levels — do not combineUse sequentially, not concurrently.
Bisphosphonates (zoledronic acid, alendronate) or denosumabSynergistic bone-protection effect — standard combinationAdd when osteopenia develops on AI therapy.
Strong CYP3A4 inhibitors / inducersModest effect on anastrozole levels — clinical significance unclearNo routine dose adjustment.
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib)Standard combination for first-line metastatic HR+ breast cancerSpecialist oncology prescribing.

Storage Instructions

  • Store at room temperature, 15–25°C. Keep in original blister.
  • Keep out of reach of children and pets.
  • Return unused tablets to a pharmacy for disposal.

Related Alternatives on MedsBase

Other oncology medications stocked alongside this product:

Browse all anti-cancer medications →

Frequently Asked Questions

Why is Anaridex only used in postmenopausal women?

In premenopausal women, the hypothalamic-pituitary axis responds to falling oestrogen by raising LH/FSH and increasing ovarian aromatase, defeating the suppression. Anastrozole is therefore ineffective in premenopausal women as monotherapy. The standard endocrine therapy in premenopausal HR+ breast cancer is tamoxifen; in higher-risk premenopausal patients, AI + GnRH agonist (ovarian suppression) is sometimes used under specialist supervision.

How long do I take Anaridex for?

Standard adjuvant duration is 5 years. For higher-risk node-positive disease, extended therapy to 7–10 years is increasingly recommended (extrapolated from ATLAS and aTTom tamoxifen data and AI extension trials such as MA.17R). For metastatic disease, anastrozole continues until progression or intolerable toxicity.

How do I manage joint pain on Anaridex?

Aromatase inhibitor arthralgia affects ~30% of patients and is the main reason for premature discontinuation. First-line measures: regular weight-bearing exercise (yoga, walking, swimming), vitamin D 1,000–2,000 IU/day, paracetamol or short courses of NSAIDs, weight management. If intolerable, switching to letrozole or exemestane sometimes helps — about 30% of patients tolerate one AI but not another.

Will Anaridex weaken my bones?

Yes — aromatase inhibitors accelerate bone-density loss with about 30% increased fracture risk versus tamoxifen. Mandatory baseline DEXA scan, repeat every 2 years. Calcium + vitamin D supplementation is standard. If osteopenia develops, add a bisphosphonate (zoledronic acid IV every 6 months) or denosumab (60 mg SC every 6 months) — this is now standard of care and should be discussed with the oncologist.

Can I use vaginal oestrogen for dryness while on Anaridex?

Generally not recommended — even low-dose vaginal oestrogen produces measurable systemic absorption that can defeat AI therapy. First-line: non-hormonal vaginal moisturisers (Replens, hyaluronic acid gels) and water-based lubricants. If symptoms are intolerable, a specialist may consider very low-dose vaginal oestriol on an individual risk-benefit basis (vaginal oestriol has lower systemic absorption than oestradiol).

Anaridex vs tamoxifen vs letrozole vs exemestane — which is right for me?

This is an oncologist decision based on your menopausal status, tumour biology, and side-effect profile. Broad pattern: premenopausal HR+tamoxifen first-line. Postmenopausal HR+ → AI (anastrozole / letrozole / exemestane) first-line, with switch to tamoxifen as 2nd-line if AI intolerance. The three AIs have similar efficacy. Anastrozole and letrozole are non-steroidal; exemestane is steroidal and structurally distinct. Switching between AIs is reasonable for intolerable side effects.

Is Anaridex safe in pregnancy?

Absolutely not. Anastrozole is contraindicated in pregnancy and breastfeeding. Postmenopausal patients are usually past childbearing potential, but perimenopausal patients (chemotherapy-induced amenorrhoea may not be permanent) need reliable non-hormonal contraception throughout treatment.

Can I take Anaridex with my heart medications?

Anastrozole has minimal direct interactions with cardiovascular medications. The relevant clinical concern is the small increased risk of ischaemic cardiac events on AI therapy versus tamoxifen, particularly in patients with established cardiac disease. Optimise modifiable cardiac risk factors (statins for hyperlipidaemia, BP control, smoking cessation, exercise) and discuss any chest pain promptly.

What happens if I stop Anaridex early?

Stopping adjuvant aromatase inhibitor therapy before completion of the planned 5–10 years course significantly increases breast cancer recurrence risk. Real-world data show that fewer than 50% of patients complete the full 5 years — usually because of arthralgia and quality-of-life impact. Always discuss intolerable side effects with your oncologist before stopping — switching AI, dose modifications, supportive care, and acupuncture for arthralgia are all options before discontinuation.

Why order from MedsBase

Every batch is sourced from a WHO-GMP certified manufacturer. Orders are dispatched in plain, unbranded packaging from our fulfilment partners and covered by our Reshipment Assurance Policy: if a parcel does not arrive within 20 business days we send a free reshipment, no questions asked.

Related Anti-Cancer Medications

Other oncology medications stocked alongside this product:

More options in Anti Cancer Medication

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Strength

1 mg

Quantity

30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s

Q & A

Ask a question
Anaridex Anaridex
Your question
* Question is required
Name
* Name is required
There are no questions yet